I now have two major areas of research: The CAPP programme has now succeeded in establishing that aspirin significantly reduces the risk of cancer in people with Lynch syndrome, the major form of hereditary colorectal cancer. We are now poised to transform the clinical management of cancer in all people with a family history. I am Chief Investigator of the CaPP3 trial, a dose non-inferiority study to determine the optimal dose of aspirin for cancer chemoprevention in Lynch Syndrome, will reach last Patient Last Visit in June 2024. 1879 carriers of Lynch Syndrome have been randomised in the UK, Finland, Spain, Israel and Australia. CAPP2 also demonstrated a major reduction of non-colorectal cancers in those randomised to resistant starch (high fibre) supplements.